Multiple sclerosis patients are missing out on drugs.


Only 40% of people eligible for drugs to combat multiple sclerosis in the UK are actually taking them, says a report from the MS Society.

A survey of more than 10,000 adults with MS showed that many were missing out on the seven licensed medicines approved for use.

The charity said a lack of information and access to specialists was to blame.

_67258385_multiple_sclerosis_treatment-spl

It is calling for the government to provide a personalised care plan to every person with MS.

The MS Society’s survey and accompanying report showed that there were differences in access to disease-modifying treatments (DMTs) across the four nations of the UK.

These are medicines that can reduce the frequency and severity of MS attacks, and in some cases can slow the progression of the disabling condition.

Someone living in Northern Ireland with MS was twice as likely to be taking a DMT (68%) than someone with the condition in Wales (30%), for example.

Access to treatment in Scotland and England was only a little higher at 36% and 40%.

What is multiple sclerosis?

Multiple sclerosis (MS) is a neurological condition that affects around 100,000 people in the UK.

Most patients have it diagnosed between the ages of 20 and 40, but it can affect younger and older people too.

Almost three times as many women as men have MS.

In Europe, additional research shows that only Poland and Romania have a smaller proportion of people with MS taking licensed medicines.

Routine assessment

The charity’s report said that being well informed about the medicines available was crucial.

Those who felt they had enough information about medicines were 32% more likely to be taking a DMT, the survey found, and those with access to a specialist MS nurse or neurologist were more than twice as likely to be taking the appropriate drugs.

Northern Ireland is the only place in the UK where most people with MS are routinely invited every six months to see a neurologist or MS nurse for a review.

This means that people with MS are constantly having their treatment options assessed, the report says.

As a result, they are more likely to get the information they need and discuss issues such as side-effects.

UK licensed medicines for MS

  • Avonex, Betaferon, Rebif and Copaxone were all made available on the NHS in 2002 throughout the UK.
  • Extavia was licensed in 2009 and reduces relapses by a third.
  • Tysabri is a monthly infusion administered by a healthcare professional. It can reduce the number of relapses by an estimated 67% and slow disability. It was approved for use on the NHS across the UK in 2007.
  • Gilenya, the first pill for MS, is said to reduce relapse rates by 54-60% and slows disability progression by around 30%. It was approved in 2012.

Yet this may not be the only solution. Forty-one per cent of those who said they did have enough information about drug treatments still did not take a disease-modifying treatment.

The report concluded: “This could be due to barriers to accessing medicines; because individuals make an informed decision not to take them; or because they don’t know what information is out there that they could have access to, such as around new treatments or new evidence of efficacy.”

New policy

Nick Rijke, director for policy and research at the MS Society, said people with multiple sclerosis were facing a lottery.

“These findings worryingly suggest that the likelihood of someone receiving a life-changing treatment is often based on luck – like where they live or how helpful their healthcare professional is – rather than their genuine clinical need.

“When it comes to prescription rates, the UK ranks 25th out of 27 European countries. Given the relative wealth of the UK this is simply unacceptable.”

The MS Society is now calling on all four governments in the UK to ensure every person with MS has a personalised treatment, care and support plan, with two comprehensive reviews each year.

Ed Holloway, head of care and services research at the MS Society, said that because some MS drugs were costly, they were often not offered when they should be because of restricted NHS budgets.

A spokesman for NHS England, which has recently taken on the commissioning of treatment for MS from primary care trusts, said a new policy from 1 April would mean that people across England would have the same access to treatment.

“By making decisions nationally about specialist treatments, we are confident that patients will now be able to receive the treatment they need, irrespective of where they live.

“As with all policies, we will continue to collect and review the outcome of treatments for patients and consider them when our policy is reviewed.

“If a patient has concerns about the treatment they are receiving we would urge them to speak to their GP or consultant.”

Source:BBC

 

 

 

Drug licensed for advanced rare skin cancer.


Cancer experts have welcomed a move that makes a drug for patients with advanced skin cancer available in the UK.
Regulators have licensed Erivedge (vismodegib) for people with severe basal skin carcinoma.
Currently, treatment is limited to surgery or radiotherapy.
Cancer Research UK, whose scientists discovered the mechanisms the drug uses, said the decision was “great news for patients”.
Basal cell carcinoma is the most common form of skin cancer in the UK and is often found on the head and neck.
Around 700 people a year in the UK are diagnosed with an advanced form of the cancer – a small number, but cancer experts say the lack of treatment options currently available is what makes this change significant.
Many will have already had surgery and radiotherapy, and it is often considered inappropriate for them to have further procedures
Continue reading the main story
“Start Quote
“This drug is a major advance for the treatment of this disease” ”
Dr Harpal KumarCancer Reseach UK
Erivedge, made by Roche, had to be licensed by the European Medicines Agency before it could be made available in the UK.
The drug, which patients take once a day, costs around £6,000 per month.
Clinicians who want to give it to their patients will have to apply to the Cancer Drugs Fund in England.
In Scotland, Wales and Northern Ireland, doctors would have to ask their local health provider to fund the drug.
Hedgehog pathway
The drug works by blocking a process in the body that has gone awry.
The hedgehog pathway is a chemical process that is normally only active in the early stages of life and which becomes less so in adulthood.
The reactivation of this process is responsible for cell growth in more than 90% of basal cell carcinoma cases.
Dr Harpal Kumar, chief executive of Cancer Research UK, said: “We are proud to have played a key role in the early development of this drug and we’re delighted that it has passed this regulatory hurdle and is approved for use in the UK.
“This drug is a major advance for the treatment of this disease, providing advanced basal cell carcinoma patients with a new treatment option.
“This is great news for patients.”
Source: Cancer experts have welcomed a move that makes a drug for patients with advanced skin cancer available in the UK.
Regulators have licensed Erivedge (vismodegib) for people with severe basal skin carcinoma.
Currently, treatment is limited to surgery or radiotherapy.
Cancer Research UK, whose scientists discovered the mechanisms the drug uses, said the decision was “great news for patients”.
Basal cell carcinoma is the most common form of skin cancer in the UK and is often found on the head and neck.
Around 700 people a year in the UK are diagnosed with an advanced form of the cancer – a small number, but cancer experts say the lack of treatment options currently available is what makes this change significant.
Many will have already had surgery and radiotherapy, and it is often considered inappropriate for them to have further procedures
Continue reading the main story
“Start Quote
“This drug is a major advance for the treatment of this disease” ”
Dr Harpal KumarCancer Reseach UK
Erivedge, made by Roche, had to be licensed by the European Medicines Agency before it could be made available in the UK.
The drug, which patients take once a day, costs around £6,000 per month.
Clinicians who want to give it to their patients will have to apply to the Cancer Drugs Fund in England.
In Scotland, Wales and Northern Ireland, doctors would have to ask their local health provider to fund the drug.
Hedgehog pathway
The drug works by blocking a process in the body that has gone awry.
The hedgehog pathway is a chemical process that is normally only active in the early stages of life and which becomes less so in adulthood.
The reactivation of this process is responsible for cell growth in more than 90% of basal cell carcinoma cases.
Dr Harpal Kumar, chief executive of Cancer Research UK, said: “We are proud to have played a key role in the early development of this drug and we’re delighted that it has passed this regulatory hurdle and is approved for use in the UK.
“This drug is a major advance for the treatment of this disease, providing advanced basal cell carcinoma patients with a new treatment option.
“This is great news for patients.”
Source: BBC

 

Babies to be offered vomiting bug vaccine.


An extra vaccination is to be offered to babies in England, Wales and Northern Ireland to protect them against a vomiting and diarrhoea bug.

Rotavirus infection is the most common cause of gastroenteritis (vomiting and diarrhoea) in children under five._68442595_oralvaccine

Nearly every child currently gets the condition by the time they are five.

But experts hope the oral vaccine, given to babies at two and three months old, will halve the number of cases seen annually.

The bug currently accounts for 130,000 visits to the GP and 13,000 hospital visits for dehydration every year.

Scotland introduced a rotavirus vaccine in May.

‘Protect your baby’

Dr Paul Cosford, director for health protection and medical director at Public Health England, said: “Rotavirus is a highly infectious and unpleasant illness that affects thousands of young children each year.

Continue reading the main story

“Start Quote

The best way to protect your baby from catching rotavirus is to get them vaccinated”

Dr Paul Cosford,Public Health England

“While most recover within a few days, nearly one in five will need to see their doctor, and one in 10 will end up in hospital as a result.”

He added: “Although good hygiene measures can help prevent spread of the disease, the best way to protect your baby from catching rotavirus is to get them vaccinated.

“The new vaccine will provide protection to those young babies who are most vulnerable to complications arising from rotavirus.

“From now on, parents will be offered this protection alongside their baby’s other childhood vaccinations.”

Further new vaccinations against shingles, meningococcal C and flu will be introduced later this year.

Source: BBC

Force-Feeding, Autonomy, and the Public Interest.


Hunger striking is a nonviolent act of political protest. It is not the expression of a wish to die, nor is it akin to the decision of a terminally ill patient to discontinue food and fluid intake. Rather, it is brinkmanship. Faced with hunger-striking detainees, prison authorities have three choices: force-feed the hunger strikers, let them die, or accede to their demands.

As the World Medical Association (WMA) suggests, most bioethicists unequivocally oppose force-feeding. Enteral feeding through a nasogastric tube while a detainee is strapped to a chair violates a mentally competent patient’s right to refuse treatment and is physically violent.1 The WMA is less categorical about artificially feeding unconscious or delirious hunger strikers through their abdominal wall. Under these circumstances, physicians may permissibly weigh their patient’s best interests and prior expressions of intent before deciding about continued treatment.

Physicians who care for hunger-striking detainees weigh autonomy and best interests; rarely must they consider security interests. Local authorities, however, do not have this prerogative. Whereas bioethicists are keen to uphold autonomy and avoid force-feeding, public officials are bound to maintain public order and prevent the deaths of detainees. Those responsibilities leave officials only two choices: forced or artificial feeding, or accommodation. Accommodation deserves first consideration because it may be a reasonable choice. Faced with hunger-striking Palestinian detainees in 2012–2013, for example, Israeli officials satisfied some prisoners by improving prison conditions or modifying their prison terms. Similarly, the Turkish government met some hunger strikers’ demands last year. In each case, the hunger strike ended. Strikers played their hands deftly, carefully choosing realistic aims and employing nonviolent protests to gain symbolic but important concessions. Local medical organizations also played a role: the Israeli Medical Association instructed its members to comply with WMA guidelines, thereby pushing public officials to earnestly explore accommodation.2

The situation at Guantanamo deserves similar creativity. The detainees’ demands are not monolithic. Prisoners who are cleared for release require expedited repatriation, whereas others may be satisfied with customary legal proceedings, better prison conditions, or both. Accommodating the protesters on some counts may not be impossible. But whereas the freed Palestinian hunger strikers were previously paroled prisoners, not public enemies, some Guantanamo detainees may be militants representing genuine security threats, and authorities may not be able to meet all their demands. Nor is it sensible to let prisoners die: widespread rioting, civil unrest, and attacks on military and civilian personnel often follow the deaths of hunger strikers. And if one cannot allow hunger strikers to die or accede to their demands, then force-feeding must be back on the table.

There is no doubt that when mentally competent people refuse to eat or be fed, force-feeding or artificially feeding them violates the principle of autonomy. But autonomy is not sacrosanct. Persuasive moral arguments appeal to the sanctity of life to permit caregivers to override respect for autonomy when necessary to avert an easily preventable death from starvation.3,4 Respect for autonomy, moreover, conflicts with other important, nonmedical principles. Among military personnel, for example, autonomy, privacy, and the right to refuse certain treatments are limited and subordinate to security interests and the conditions necessary to maintain a fighting force.5 Similarly, the imperative to respect a detainee’s right of informed consent is not obviously superior to the interests of public security. There are usually good reasons for keeping captured enemy combatants locked up and alive. In fact, that is the norm of military detention. A prisoner’s desire to go free or die trying cannot override this basic interest of the state. A democratic government cannot be so hamstrung that the possibility of viable incarceration evaporates.

Of course, this argument should not be construed as permission to violate a fundamental human right in the name of military necessity. But the right of informed consent is not such a fundamental right — it is subordinate to human rights that protect people from murder, servitude, torture, and cruelty. One might argue, then, that force-feeding assaults a person’s dignity, and surely that is true when the feeding is accompanied by physical violence. But that argument does not repudiate force-feeding; it only mandates a search for nonviolent and humane methods.

Two practical difficulties also plague any directive to prioritize autonomy. First, respecting autonomy requires firm knowledge of a striker’s intent, which caregivers and prison authorities are unlikely to have. Given the lack of continuity of care, along with cultural differences, language barriers, and instructions that detainees may have received from their leaders, it would be extraordinarily difficult for anyone to determine whether a detainee was acting autonomously or under duress. Under these circumstances, the case for autonomous decision making weakens sufficiently to allow physicians to weigh a patient’s best interest over his or her decision to refuse food. Second, clinicians face a crisis of confidentiality if hunger strikers agree to accept food and fluids once their condition deteriorates but demand that caregivers keep these instructions secret. In these instances, confidentiality maximizes a striker’s political leverage, draws doctors into the fight, and leaves medical workers to stand by helplessly if public officials make suboptimal decisions on the basis of erroneous information.

The moral and practical difficulties of dogmatically upholding respect for autonomy suggest that the WMA would not allow physicians to stand by and watch hunger strikers die. It is unimaginable that any decent society today would leave 10 Irish Republican Army hunger strikers to die of starvation as the British did in Northern Ireland in 1981. Accounts of their slow and anguished deaths are harrowing, and no rights-respecting government or medical association should ever permit a repetition of that event. Instead, we should think about how to feed hunger strikers humanely. Once respect for autonomy falls to best interests or public interests, it makes no difference whether the authorities turn to humane force-feeding or to artificial feeding. But artificial feeding is not ideal: though less aggressive than force-feeding, it is also less salubrious — surely it is healthier to prevent starvation than to treat it. Politically, hunger strikes only galvanize prisoners and enflame their supporters. Letting strikes drag out until detainees are at death’s door is not a solution.

Hunger strikes by security detainees pose an excruciating dilemma. Physicians who decry disrespect of autonomy are left to watch treatable patients die. Physicians who extol the sanctity of life are committed to feeding healthy inmates by force. Public officials can neither accede to inmates’ demands nor allow them to die when negotiations stall but instead require humane methods to keep inmates alive. In this environment, the medical community faces two challenges. First, health care professionals will be called on to develop and administer humane methods for feeding striking detainees while providing general medical care under trying prison conditions. Second, health care professionals must also continue to scrutinize the behavior of public officials, cognizant of the medical interests of their patients and the collective interests of their community. Force-feeding should be rare, the product of serious but ultimately unsuccessful negotiations with strikers.

These are not easy straits to navigate. Armed conflict and other public emergencies pit personal, professional, and public interests against one another. Medical professionals, like other citizens in a thriving democracy, must simultaneously sustain the efforts of war and contain them.

 

Source: NEJM

 

 

 

Public Health England to launch largest cancer database


_68124677_c0148937-dividing_liver_cancer_cell,_sem-spl

The world’s largest database of cancer patients is being set up in England in an attempt to revolutionise care, Public Health England has announced.

It will collate all the available data on each of the 350,000 new tumours detected in the country each year.

The aim is to use the register to help usher in an era of “personalised medicine” that will see treatments matched to the exact type of cancer a patient has.

Experts said it was “great news”.

The old definitions of cancer – breast, prostate, lung – are crumbling.

Cancer starts with a mutation that turns a normal cell into one that divides uncontrollably and becomes a tumour. However, huge numbers of mutations can result in cancer and different mutations need different treatments.

Research into the genetics of breast cancer means it is now thought of as at least 10 completely separate diseases, each with a different life expectancy and needing a different treatment.

The national register will use data from patients at every acute NHS trust as well 11 million historical records.

Continue reading the main story

“Start Quote

It’ll be easier and quicker to further cancer research, and will speed up work to deliver personalised cancer medicine to patients in the future.”

Emma GreenwoodCancer Research UK

It will eventually track how each sub-type of cancer responds to treatment, which will inform treatment for future patients.

‘Fundamental change’

Jem Rashbass, national director of disease registration at Public Health England, said: “Cancer-registry modernisation in England is about to deliver the most comprehensive, detailed and rich clinical dataset on cancer patients anywhere in the world.”

He told the BBC: “This will fundamentally change the way we diagnose and treat cancer.

“In five years we’ll be sequencing cancers and using therapies targeted to it.”

The service will also exchange information with Wales, Scotland and Northern Ireland, which have their own registers.

The Department of Health has already committed £100m to sequence the entire genetic code of 100,000 patients with cancer and rare diseases in order to accelerate progress in personalised medicine.

Emma Greenwood, Cancer Research UK’s head of policy development, said: “It’s great news that this national database has been set up.

“It means we have all the UK’s cancer information in one place, making us well equipped to provide the highest quality care for every cancer patient.

“It’ll be easier and quicker to further cancer research, and will speed up work to deliver personalised cancer medicine to patients in the future.”

Source: BBC

A tax on indoor tanning would reduce demand in Europe.


The use of indoor tanning beds has been established to be a serious risk to human health.1 In the European Union, Northern Ireland is the latest country to pass legislation that prohibits under 18s from using indoor tanning equipment. Although this will protect children from this risk, more needs to be done if we are to respond to the International Agency for Research on Cancer’s suggestion that we need also to “discourage young adults from using indoor tanning equipment.”1

Globally, the incidence of cutaneous melanoma has increased faster than any other common cancer, with an approximate doubling of rates every 10-20 years in countries with predominantly white populations.2 For instance, in 2008 there were about 70 000 incidences of, and more than 14 000 deaths from, melanoma in the European Union.3 Although attempts at public education by health agencies and charities have increased, these are being obscured by spurious claims by the indoor tanning industry of the benefits of indoor tanning.4

Recent lessons from tobacco control in the EU teach us that tax increases are the single most effective intervention to reduce demand for harmful products.5 The EU needs to follow the example of the United States by introducing a so called tan tax; an excise on indoor tanning services. A new EU directive for the taxation of indoor tanning services would complement existing directives focused on product safety.6 Importantly, these excise duties would provide additional revenue for governments and reduce numbers of melanomas and other skin cancers—something that would also subsequently reduce governments’ healthcare costs. All or a portion of this revenue could be earmarked for public health education initiatives warning of the dangers of ultraviolet radiation exposure.

Source: BMJ

Antibiotic Stewardship Program Reduces C. difficile Infection Rates.


Restricted cephalosporin, fluoroquinolone, and clindamycin use was associated with reduced antibiotic consumption and a decline in the incidence trend of Clostridium difficile infection.

Use of cephalosporins, fluoroquinolones, and clindamycin has repeatedly been associated with increased risk for Clostridium difficile infection (CDI). However, little is known about how CDI rates are affected by antibiotic stewardship programs aimed at decreasing the administration of such “high-risk” antibiotics.

Researchers recently described their experience with a restriction policy for second- and third-generation cephalosporins, fluoroquinolones, and clindamycin at a hospital in Northern Ireland that became effective in January 2008, after a major CDI outbreak in other, affiliated institutions. The policy was devised based on a time-series analysis involving one of these affiliated institutions for the period February 2002 through March 2007, which suggested that treatment of 14 patients with second-generation cephalosporins or 8 with third-generation cephalosporins — versus 94 with amoxicillin/clavulanic acid or 78 with macrolides — would result in one CDI case (Antimicrob Agents Chemother 2009; 53:2082).

Cephalosporins, quinolones, and clindamycin were prescribed significantly less frequently during the study period following implementation of the restriction policy (January 2008–June 2010) than during the 4-year preimplementation period; the use of other antibiotics remained unchanged. The intervention resulted in an overall reduction in antibiotic use and a reversal of the increasing trend for antibiotic consumption. These changes were associated with a significant decline in the incidence trend for CDI (rate decrease, 0.047/1000 bed-days per month). Variations in CDI incidence were affected by the Charlson patient comorbidity index, with a lag of 1 month.

Comment: This report on a successful antibiotic stewardship intervention is a nice example of the cause–effect relationship between antibiotic use and the occurrence of potentially serious nosocomial infections. The authors note that an antimicrobial-management team’s close surveillance of prescribing was key to successful implementation of the restriction policy.

Sourc: Journal Watch Infectious Disease.